Equities research analysts at Morgan Stanley began coverage on shares of Grail (NASDAQ:GRAL - Get Free Report) in a research report issued on Wednesday,Briefing.com Automated Import reports. The brokerage set an "equal weight" rating and a $16.00 price target on the stock. Morgan Stanley's target price would indicate a potential downside of 8.68% from the stock's current price.
A number of other equities research analysts have also issued reports on the stock. Guggenheim began coverage on shares of Grail in a report on Thursday, October 17th. They set a "neutral" rating for the company. Wolfe Research initiated coverage on Grail in a report on Friday, November 15th. They issued a "peer perform" rating for the company.
View Our Latest Report on Grail
Grail Trading Down 0.9 %
NASDAQ GRAL opened at $17.52 on Wednesday. The firm has a 50 day moving average price of $14.15. Grail has a 1-year low of $12.33 and a 1-year high of $23.36.
Insider Activity
In other news, CEO Robert P. Ragusa sold 123,454 shares of the company's stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $14.02, for a total transaction of $1,730,825.08. Following the sale, the chief executive officer now owns 612,661 shares of the company's stock, valued at approximately $8,589,507.22. This represents a 16.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Chun R. Ding bought 7,629 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were bought at an average cost of $13.52 per share, with a total value of $103,144.08. Following the completion of the purchase, the insider now directly owns 3,503,655 shares in the company, valued at $47,369,415.60. This represents a 0.22 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 58,829 shares of company stock valued at $757,298 in the last quarter.
About Grail
(
Get Free Report)
GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Grail, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.
While Grail currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
